Key Roles

• Founder/CEO of Introgen Therapeutics, Shenzhen SiBiono GeneTech and GenStar Therapeutics.
• Pioneer in Gene Therapy, Biopharma Entrepreneur & Innovator
• Developed Gendicine, the world’s first approved gene therapy (China SFDA, 2003) for cancer.
• Strategic Leader: Raised $50M+ for biotech ventures; co-founded a $300M VC/PE fund in China.

Career Highlights

• Innovation: Invented MiniAdFVIII (hemophilia therapy), led GenStar to NYSE listing (corporate value surged 100x to $600M).
• R&D Legacy : Developed 2,600+ recombinant proteins, 800+ antibodies and 36 ELISA kits.
• Corporate Leadership: Directed Baxter Healthcare’s Gene Therapy Unit ($80M annual budget), fostering global R&D partnerships.

Education & Academic

• MD (Zhejiang University), PhD (Molecular Biology, University of Alabama).
• Former Faculty: Baylor College of Medicine. MD Anderson Cancer Center.
• 16 Patents 65+ Publications in gene therapy and molecular biology.

Impacts

• Bridged lab-to-market gaps in gene therapy, advancing oncology and rare disease treatments.
• Global influencer in biopharma commercialization and precision medicine.